AI assistant
Telix Pharmaceuticals Ltd — Call Transcript 2018
Nov 25, 2018
31324_rns_2018-11-25_3f697080-0ae3-4c22-861f-92926da003cd.pdf
Call Transcript
Open in viewerOpens in your device viewer
==> picture [143 x 79] intentionally omitted <==
==> picture [171 x 39] intentionally omitted <==
Advanced Nuclear Medicine Ingredients (ANMI) SA transaction – Conference Call
Melbourne (Australia), Brussels and Liège (Belgium) – 26[th] November 2018 . Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), today announced that it has acquired Belgium-based Advanced Nuclear Medicine Ingredients (ANMI) SA. To facilitate shareholder queries, the Company will conduct an investor conference call as part of the transaction.
Investor Conference Call
9:00am AEDT on Friday 30 November 2018 to discuss the transaction. Participants can register for the conference call at the following link:
https://services.choruscall.com.au/diamondpass/telixpharma-684982-invite.html
You will receive a calendar notification with dial in details and a PIN for fast track access to the call. Alternative, participants may dial in using the details below at the scheduled time:
Conference ID: 684 982
| Australia Toll Free: | 1 800 558 698 |
|---|---|
| Alternate Australia Toll Free: | 1 800 809 971 |
| Australia Local: | 02 9007 3187 |
| New Zealand Toll Free: | 0800 453 055 |
| NZ Local (Auckland): | 09 929 1687 |
| NZ Local (Wellington): | 04 974 7738 |
| NZ Local (Christchurch): | 03 974 2632 |
| China Wide: | 4001 200 659 |
| Belgium: | 0800 72 111 |
| Canada: | 1855 8811 339 |
| France: | 0800 913 848 |
| Germany: | 0800 182 7617 |
| Hong Kong: | 800 966 806 |
| India: | 0008 0010 08443 |
| Indonesia: | 001 803 019 3275 |
| Ireland: | 1800 948 625 |
| Italy: | 800 793 500 |
| Japan: | 0053 116 1281 |
| Malaysia: | 1800 816 294 |
| Norway: | 800 69 950 |
| Philippines: | 1800 1110 1462 |
| Singapore: | 800 101 2785 |
| South Korea: | 00 798 142 063 275 |
| Sweden: | 020 791 959 |
| South Africa: | 0800 999 976 |
==> picture [143 x 79] intentionally omitted <==
==> picture [171 x 39] intentionally omitted <==
Switzerland: 0800 820 030 Taiwan: 008 0112 7397 Thailand: 001800 156 206 3275 UAE: 8000 3570 2705 United Kingdom: 0800 051 8245 United States: (855) 881 1339 US Local (New York): (914) 202 3258 US Local (Los Angeles): (909) 235 4020 US Local (Chicago): (815) 373 2080
Telix Corporate Contact
Dr Christian Behrenbruch Telix Pharmaceuticals Limited CEO Email: [email protected]
Telix Investor Relations (Australia)
Arthur Chan WE Buchan Tel: +61 2 9237 2805 Email: [email protected]
Telix Investor Relations (US)
Lisa Wilson In-Site Communications Tel: +1 212 452 2793 Email: [email protected]
Important Information
This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “US Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available. None of the products described in this release have obtained a marketing authorization in any jurisdiction, including the United States and Europe.